CSF3 and neutropenia: Furthermore, our preclinical observation that exogenous G-CSF promotes tumor cell survival and attenuates cisplatin efficacy supports a biomarker-informed, guideline-directed risk–benefit appraisal within established indications for neutropenia prophylaxis.